832 related articles for article (PubMed ID: 9113119)
1. A report comparing the use of tropisetron (Navoban), a 5-HT3 antagonist, with a standard antiemetic regimen of dexamethasone and metoclopramide in cisplatin-treated patients under conditions of severe emesis.
Madej G; Krzakowski M; Pawinski A; Lasota W; Rogowski W; Skoneczna I
Semin Oncol; 1994 Oct; 21(5 Suppl 9):3-6. PubMed ID: 9113119
[TBL] [Abstract][Full Text] [Related]
2. Tropisetron (Navoban) alone and in combination with dexamethasone in the prevention of chemotherapy-induced emesis: the Nordic experience.
Sorbe BG
Semin Oncol; 1994 Oct; 21(5 Suppl 9):20-6. PubMed ID: 9113123
[TBL] [Abstract][Full Text] [Related]
3. Prevention of chemotherapy-induced nausea and vomiting by tropisetron (Navoban) alone or in combination with other antiemetic agents.
Bruntsch U; Drechsler S; Eggert J; Gosse H; Ukena D; Imhoff W; Faerber L
Semin Oncol; 1994 Oct; 21(5 Suppl 9):7-11. PubMed ID: 9113120
[TBL] [Abstract][Full Text] [Related]
4. Prevention of emesis by tropisetron (Navoban) in children receiving cytotoxic therapy for solid malignancies.
Otten J; Hachimi-Idrissi S; Balduck N; Maurus R
Semin Oncol; 1994 Oct; 21(5 Suppl 9):17-9. PubMed ID: 9113122
[TBL] [Abstract][Full Text] [Related]
5. Navoban (tropisetron) alone and in combination with dexamethasone in the prevention of chemotherapy-induced nausea and vomiting: the Nordic experience. The Nordic Antiemetic Trial Group.
Sorbe BG; Högberg T; Glimelius B; Schmidt M; Wernstedt L; Andersson H; Hansen O; Sørensen BT; Räisänen I
Anticancer Drugs; 1995 Feb; 6 Suppl 1():31-6. PubMed ID: 7749168
[TBL] [Abstract][Full Text] [Related]
6. A study evaluating the efficacy and tolerability of tropisetron in combination with dexamethasone in the prevention of delayed platinum-induced nausea and emesis.
Sorbe BG; Berglind AM; Andersson H; Boman K; Högberg T; Hallgren M; Schmidt M
Cancer; 1998 Sep; 83(5):1022-32. PubMed ID: 9731907
[TBL] [Abstract][Full Text] [Related]
7. The oral NK(1) antagonist, aprepitant, given with standard antiemetics provides protection against nausea and vomiting over multiple cycles of cisplatin-based chemotherapy: a combined analysis of two randomised, placebo-controlled phase III clinical trials.
de Wit R; Herrstedt J; Rapoport B; Carides AD; Guoguang-Ma J; Elmer M; Schmidt C; Evans JK; Horgan KJ
Eur J Cancer; 2004 Feb; 40(3):403-10. PubMed ID: 14746859
[TBL] [Abstract][Full Text] [Related]
8. Dose comparison of tropisetron (Navoban) 5 mg and 10 mg orally in the prophylaxis of dacarbazine-induced nausea and emesis.
Garbe C; Drechsler S; Fiedler H; Tilgen W; Landthaler M; Schroeder K; Kuehne KH; Faerber L
Semin Oncol; 1994 Oct; 21(5 Suppl 9):12-6. PubMed ID: 9113121
[TBL] [Abstract][Full Text] [Related]
9. Optimal combination therapy with Navoban (tropisetron) in patients with incomplete control of chemotherapy-induced nausea and vomiting. The Belgian Navoban Group.
Van Belle SJ; Cocquyt VF; Bleiberg H; Canon JL; Buyse M; Hulstaert F; De Witte M; De Keyser P; Westelinck K
Anticancer Drugs; 1995 Feb; 6 Suppl 1():22-30. PubMed ID: 7749166
[TBL] [Abstract][Full Text] [Related]
10. Is Navoban (tropisetron) as effective as Zofran (ondansetron) in cisplatin-induced emesis? The French Navoban Study Group.
Marty M; Kleisbauer JP; Fournel P; Vergnenegre A; Carles P; Loria-Kanza Y; Simonetta C; de Bruijn KM
Anticancer Drugs; 1995 Feb; 6 Suppl 1():15-21. PubMed ID: 7749165
[TBL] [Abstract][Full Text] [Related]
11. Comparison of granisetron, ondansetron, and tropisetron in the prophylaxis of acute nausea and vomiting induced by cisplatin for the treatment of head and neck cancer: a randomized controlled trial.
Mantovani G; Macciò A; Bianchi A; Curreli L; Ghiani M; Proto E; Santona MC
Cancer; 1996 Mar; 77(5):941-8. PubMed ID: 8608488
[TBL] [Abstract][Full Text] [Related]
12. A randomized, multicenter study comparing the efficacy and tolerability of tropisetron, a new 5-HT3 receptor antagonist, with a metoclopramide-containing antiemetic cocktail in the prevention of cisplatin-induced emesis.
Sorbe BG; Högberg T; Glimelius B; Schmidt M; Wernstedt L; Hansen O; Sörensen BT; Räisänen I; van Oosterom AT; de Bruijn KM
Cancer; 1994 Jan; 73(2):445-54. PubMed ID: 8293412
[TBL] [Abstract][Full Text] [Related]
13. Establishing the dose of the oral NK1 antagonist aprepitant for the prevention of chemotherapy-induced nausea and vomiting.
Chawla SP; Grunberg SM; Gralla RJ; Hesketh PJ; Rittenberg C; Elmer ME; Schmidt C; Taylor A; Carides AD; Evans JK; Horgan KJ
Cancer; 2003 May; 97(9):2290-300. PubMed ID: 12712486
[TBL] [Abstract][Full Text] [Related]
14. Study of efficacy and tolerability of tropisetron in the prevention of cisplatin induced nausea and vomiting.
Chiersilpa A; Ngow J
J Med Assoc Thai; 1999 Sep; 82(9):915-21. PubMed ID: 10561949
[TBL] [Abstract][Full Text] [Related]
15. Phase II trial of tropisetron and dexamethasone in the prevention of cisplatin-induced emesis.
Voravud N; Suwanrusmee H
J Med Assoc Thai; 2000 Jun; 83(6):668-75. PubMed ID: 10932495
[TBL] [Abstract][Full Text] [Related]
16. Prospective randomized comparison of tropisetron with and without dexamethasone against high-dose metoclopramide in prophylaxis of acute and delayed cisplatin-induced nausea and vomiting.
Malik I; Moid I; Khan Z; Hussain M
Am J Clin Oncol; 1999 Apr; 22(2):126-30. PubMed ID: 10199444
[TBL] [Abstract][Full Text] [Related]
17. Addition of the oral NK1 antagonist aprepitant to standard antiemetics provides protection against nausea and vomiting during multiple cycles of cisplatin-based chemotherapy.
de Wit R; Herrstedt J; Rapoport B; Carides AD; Carides G; Elmer M; Schmidt C; Evans JK; Horgan KJ
J Clin Oncol; 2003 Nov; 21(22):4105-11. PubMed ID: 14559891
[TBL] [Abstract][Full Text] [Related]
18. Antiemetic efficacy of three serotonin antagonists during high-dose chemotherapy and autologous stem cell transplantation in malignant lymphoma.
Slabý J; Trnený M; Procházka B; Klener P
Neoplasma; 2000; 47(5):319-22. PubMed ID: 11130251
[TBL] [Abstract][Full Text] [Related]
19. Antiemetic effect of ondansetron and dexamethasone in gynecologic malignant patients receiving chemotherapy.
Pradermdee P; Manusirivithaya S; Tangjitgamol S; Thavaramara T; Sukwattana P
J Med Assoc Thai; 2006 Oct; 89 Suppl 4():S29-36. PubMed ID: 17725140
[TBL] [Abstract][Full Text] [Related]
20. The influence of dexamethasone in the decrease of chemotherapy-induced nausea and vomiting.
Sarcev T; Secen N; Povazan Dj; Sabo A; Popovic J; Bursac D; Kakas M; Zaric B; Milovancev A
J BUON; 2007; 12(2):245-52. PubMed ID: 17600880
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
